Day: May 23, 2022

Ad hoc announcement pursuant to Art. 53 LRAprocitentan reduces blood pressure compared to placebo by week 4 of treatment, the effect is maintained and confirmed over a period of 48 weeks, and is generally well tolerated with no major safety concerns Primary and key secondary endpoints were met with statistical significance and clinically meaningful results – the effect was consistent across multiple endpoints and methodologies of blood pressure monitoring Idorsia to host an investor webcast to discuss PRECISION top-line results tomorrow May 24 at 14:00hrs CESTAllschwil, Switzerland – May 23, 2022Idorsia Ltd (SIX: IDIA) today announced positive top-line results of PRECISION, the Phase 3 study investigating aprocitentan, Idorsia’s dual endothelin receptor antagonist, for the treatment of patients whose blood pressure is not adequately...

Ordinær generalforsamling i Mowi ASA avholdes 13. juni 2022 kl. 11:00 som et digitalt møte. Innkalling med dagsorden til generalforsamlingen samt utvalgte vedlegg følger vedlagt. Innkallingen sendes i dag til alle aksjonærer. Innkallingen med samtlige vedlegg gjøres tilgjengelig på Mowis nettsider www.mowi.com/investors. Denne opplysningen er informasjonspliktig etter verdipapirhandelloven §5-12.AttachmentMOWI AGM Notice 2022 NOR

Mowi ASA’s Annual General Meeting will be held on 13 June 2022 at 11:00 CET as a digital meeting. The notice including agenda for the meeting and selected appendices are attached to this disclosure. The notice will be sent today to all shareholders. The notice with complete appendices will be made available on Mowi’s website, www.mowi.com/investors. This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.AttachmentMOWI AGM Notice 2022 ENG

–Kala Will Receive $60 Million in Upfront Payment; Eligible to Receive Additional Sales-Based Milestone Payments––Kala Will Focus Resources on Phase 2/3 Trial of KPI-012 for Orphan Disease Persistent Corneal Epithelial Defect– ARLINGTON, Mass., May 23, 2022 (GLOBE NEWSWIRE) — Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it has entered into a definitive agreement to sell its commercial portfolio and related intellectual property assets to Alcon Inc. This includes EYSUVIS, the first and only U.S. Food and Drug Administration (FDA) approved medicine for the short-term (up to two weeks) treatment of the signs and symptoms of dry eye disease,...

SHANGHAI, China, May 22, 2022 (GLOBE NEWSWIRE) — NIO Inc. (NYSE: NIO; HKEX: 9866; SGX: NIO) (“NIO” or the “Company”), a pioneer and a leading company in the premium smart electric vehicle market, today announced that it will be included in the Hang Seng TECH Index as a constituent stock, effective June 13, 2022, according to the announcement made by the Hang Seng Indexes Company Limited on May 20, 2022. The Hang Seng TECH Index represents the 30 largest technology companies listed in Hong Kong that have high business exposure to technology themes and pass the index’s screening criteria. In addition, the Company will also be included in the Hang Seng Composite Index as a constituent stock, effective June 13, 2022. About NIO Inc. NIO Inc. is a pioneer and a leading company in the premium smart electric vehicle market. Founded...

SHANGHAI, China, May 22, 2022 (GLOBE NEWSWIRE) — NIO Inc. (NYSE: NIO; HKEX: 9866; SGX: NIO) (“NIO” or the “Company”), a pioneer and a leading company in the premium smart electric vehicle market, today announced that it will report its first quarter 2022 unaudited financial results on Thursday, June 9, 2022, before the open of the U.S. markets. The Company’s management will host an earnings conference call at 8:00 AM U.S. Eastern Time on June 9, 2022 (8:00 PM Beijing/Hong Kong/Singapore Time on June 9, 2022). A live and archived webcast of the conference call will be available on the Company’s investor relations website at https://ir.nio.com/news-events/events. For participants who wish to join the conference using dial-in numbers, please register in advance using the link provided below and dial in 10 minutes prior to the call....